Dear Pharmaceutical Management Agency,

Please provide the following information:
- All correspondence relating to the Pharmac's management of the supply issue for Oestradiol (Estradot) patches, Oestradiol gel and other products. Including correspondence to Pharmacists, wholesalers, distributors, hospital pharmacists, Ministry of Health, Public Health Agency, Consumers and Advocacy Groups, PHO's and primary care organisations and other interested parties (From 2022 onwards)

- Correspondence and documents that relate to Pharmac's most recent decision to Request for Proposals for supply of transdermal oestriadol products. Please include documentation regarding the announced Tender process and current status (From 2022 onwards).

- Internal Policies and/or guidance relating to the management and access to Oestradiol (Estradot) patches, Oestradiol gel and other products.

- Correspondence and documentation that evidence Pharmac have considered the following in their management of the supply issue for Oestradiol (Estradot) patches, Oestradiol gel and other products - Impact on the wellbeing of people who are unable to receive the treatment they need, alignment with Pharmac's Achieving access equity, Human Rights considerations i.e. discrimination on the grounds of Gender and Disability, number of complaints received about the supply issue/Pharmac's management of the issue

- budget assigned to resolving the supply issue of Oestradiol (Estradot) patches, Oestradiol gel and other products.

Yours faithfully,

M Williams